GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Cyclically Adjusted PB Ratio

Biofrontera AG (XTER:B8FK) Cyclically Adjusted PB Ratio : 0.47 (As of May. 29, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Biofrontera AG's current share price is €2.49. Biofrontera AG's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was €5.25. Biofrontera AG's Cyclically Adjusted PB Ratio for today is 0.47.

The historical rank and industry rank for Biofrontera AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

XTER:B8FK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.42   Med: 4.03   Max: 259.34
Current: 0.5

During the past years, Biofrontera AG's highest Cyclically Adjusted PB Ratio was 259.34. The lowest was 0.42. And the median was 4.03.

XTER:B8FK's Cyclically Adjusted PB Ratio is ranked better than
86.85% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs XTER:B8FK: 0.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biofrontera AG's adjusted book value per share data for the three months ended in Dec. 2024 was €3.103. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.25 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofrontera AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biofrontera AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Cyclically Adjusted PB Ratio Chart

Biofrontera AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 13.88 7.13 1.65 0.41

Biofrontera AG Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.40 0.59 0.46 0.41

Competitive Comparison of Biofrontera AG's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Cyclically Adjusted PB Ratio falls into.


;
;

Biofrontera AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biofrontera AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.49/5.25
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Biofrontera AG's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=3.103/127.0412*127.0412
=3.103

Current CPI (Dec. 2024) = 127.0412.

Biofrontera AG Quarterly Data

Book Value per Share CPI Adj_Book
201503 -1.722 99.717 -2.194
201506 -2.959 100.417 -3.744
201509 -4.291 100.417 -5.429
201512 -3.061 99.717 -3.900
201603 -0.462 100.017 -0.587
201606 0.661 100.717 0.834
201609 -1.579 101.017 -1.986
201612 7.823 101.217 9.819
201703 6.132 101.417 7.681
201706 5.038 102.117 6.268
201709 2.350 102.717 2.906
201712 1.640 102.617 2.030
201803 9.616 102.917 11.870
201806 7.607 104.017 9.291
201809 5.689 104.718 6.902
201812 7.167 104.217 8.737
201903 5.909 104.217 7.203
201906 11.012 105.718 13.233
201909 6.215 106.018 7.447
201912 4.341 105.818 5.212
202003 1.859 105.718 2.234
202006 2.066 106.618 2.462
202009 -0.472 105.818 -0.567
202012 3.021 105.518 3.637
202103 9.080 107.518 10.729
202106 7.642 108.486 8.949
202109 5.631 109.435 6.537
202112 20.342 110.384 23.412
202203 10.595 113.968 11.810
202206 7.538 115.760 8.273
202209 5.735 118.818 6.132
202212 6.694 119.345 7.126
202303 5.553 122.402 5.763
202306 5.617 123.140 5.795
202309 4.571 124.195 4.676
202312 6.577 123.773 6.751
202403 5.681 125.038 5.772
202406 2.938 125.882 2.965
202409 2.791 126.198 2.810
202412 3.103 127.041 3.103

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biofrontera AG  (XTER:B8FK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biofrontera AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG Business Description

Traded in Other Exchanges
N/A
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG Headlines

No Headlines